Results 131 to 140 of about 375,043 (313)
Higher complement C4 gene copy number constitutes a shared genetic risk factor for giant cell arteritis and IgA vasculitis
Arthritis &Rheumatology, Accepted Article.Objective
Low copy number (CN) of complement C4 isoforms and high CN of retroviral HERV‐K elements are known risk factors for many immune‐mediated inflammatory diseases (IMIDs), often showing sex‐biased effects. Here, we assessed whether CN variation within the C4 gene contributes to giant cell arteritis (GCA) and IgA vasculitis (IgAV), two complex ...Laura Martínez‐Gutiérrez, Gonzalo Borrego‐Yaniz, José Hernández‐Rodríguez, Carlo Salvarani, María Cinta Cid, Ann W. Morgan, International GCA Consortium, Santos Castañeda, Roser Solans, Jaume Mestre‐Torres, Norberto Ortego‐Centeno, José Luis Callejas, Luis Caminal‐Montero, Marc Corbera‐Bellalta, Eugenio de Miguel, J. Bernardino Díaz‐López, María Jesús García‐Villanueva, Carmen Gómez‐Vaquero, Mercedes Guijarro‐Rojas, Ana Hidalgo‐Conde, Begoña Marí, Alfonso Reyes Ochoa, Agustín Martínez‐Berriochoa, Inmaculada C. Morado, Javier Narváez, Marc Ramentol‐Sintas, Aleida Martínez‐Zapico, Víctor Manuel Martínez‐Taboada, José A. Miranda‐Filloy, Jordi Monfort, Mercedes Pérez‐Conesa, Sergio Prieto‐ González, Enrique Raya, Raquel Ríos‐Fernández, Julio Sánchez Martín, Bernardo Sopeña, Laura Tío, Ainhoa Unzurrunzaga, Peter A Merkel, Nader Khalidi, Carol A. Langford, Steven Ytterberg, Simon Carette, Sharon Chung, David Cuthbertson, Lindsy J. Forbess, Ora Gewurz‐Singer, Gary S. Hoffman, Curry L. Koening, Kathleen M. Maksimowicz‐McKinnon, Carol A. McAlear, Larry W. Moreland, Christian Pagnoux, Philip Seo, Ulrich Specks, Robert F. Spiera, Antoine Sreih, Kenneth J. Warrington, Paul A. Monach, Michael Weisman, Augusto Vaglio, Lorenzo Beretta, Marcello Govoni, Giacomo Emmi, Marco A Cimmino, Carlo Salvarani, Torsten Witte, Thomas Neumann, Julia Holle, Verena Schönau, Peter Lamprecht, Sebastian Klapa, Gregory Pugnet, Thomas Papo, Julien Haroche, Alfred Mahr, Luc Mouthon, Øyvind Molberg, Andreas P. Diamantopoulo, Alexandre Voskuyl, Yannick van Sleen, Elisabeth Brouwer, Thomas Daikeler, Christoph T. Berger, Eamonn S. Molloy, UK GCA Consortium, Sarah L Mackie, Louise Sorensen, Lubna Haroon Raashid, Steve Martin, Robinson James I, Oliver Wordsworth, Isobel Whitwell, Jessica Brock, Victoria Douglas, Chamila Hettiarachchi, Jacqui Bartholomew, Stephen Jarrett, Gayle Smithson, Michael Green, Pearl Clark Brown, Cathy Lawson, Esther Gordon, Suzanne Lane, Rebecca Francis, Bhaskar Dasgupta, Bridgett Masunda, Jo Calver, Yusuf Patel, Charlotte Thompson, Louise Gregory, Sarah Levy, Ajit Menon, Amy Thompson, Lisa Dyche, Michael Martin, Charles Li, Ramasharan Laxminarayan, Louise Wilcox, Ralph de Guzman, John Isaacs, Alice Lorenzi, Gary Reynolds, Ross Farley, Helain Hinchcliffe‐Hume, Victoria Bejarano, Susan Hope, Pradip Nandi, Lynne Stockham, Catherine Wilde, Donna Durrant, Mark Lloyd, CheeSeng Ye, Rob Stevens, Amjad Jilani, David Collins, Suzannah Pegler, Ali Rivett, Liz Price, Neil McHugh, Sarah Skeoch, Diana O’Kane, Sue Kirkwood, Saravanan Vadivelu, Susan Pugmire, Shabina Sultan, Emma Dooks, Lisa Armstrong, Hala Sadik, Anupama Nandagudi, Tolu Abioye, Angelo Ramos, Steph Gumus, Nidhi Sofat, Abiola Harrison, Abi Seward, Susan Mollan, Ray Rahan, Helen Hawkins, Hedley Emsley, Anna Bhargava, Vicki Fleming, Marianne Hare, Sonia Raj, Emmanuel George, Nicola Allen, Karl Hunter, Eoin O’Sullivan, Georgina Bird, Malgorzata Magliano, Katarina Manzo, Bobbie Sanghera, David Hutchinson, Fiona Hammonds, Poonam Sharma, Richard Cooper, Graeme McLintock, Zaid S. Al‐Saffar, Mike Green, Kerry Elliott, Tania Neale, Janine Mallinson, Peter Lanyon, Marie‐Josephe Pradere, Natasha Jordan, Ei Phyu Htut, Thelma Mushapaidzi, Donna Abercrombie, Sam Wright, Jane Rowlands, Chetan Mukhtyar, James Kennedy, Damodar Makkuni, Elva Wilhelmsen, Michael Kouroupis, Shweta Bhagat, Lily John, Rod Hughes, Margaret Walsh, Marie Buckley, Kirsten Mackay, Tracey Camden‐Woodley, Joan Redome, Kirsty Pearce, Thiraupathy Marianayagam, Carina Cruz, Elizabeth Warner, Ishmael Atchia, Claire Walker, Karen Black, Stacey Duffy, Marwan Bukhari, Lynda Fothergill, Rebecca Jefferey, Jackie Toomey, Ceril Rhys Dillon, Carla Pothecary, Lauren Green, Tracey Toms, Linda Maher, Diana Davis, Amrinder Sayan, Mini Thankachen, Mahdi Abusalameh, Jessica Record, Asad Khan, Sam Stafford, Azza Hussein, Clare Williams, Alison Fletcher, Laura Johson, Richard Burnett, Robert Moots, Helen Frankland, James Dale, Karen Black, Kirsten Moar, Carol Hollas, Ben Parker, Derek Ridings, Sandhya Eapen, Sindhu John, Jo Robson, Lucy Belle Guthrie, Rose Fyfe, Moira Tait, Jonathan Marks, Emma Gunter, Rochelle Hernandez, Smita Bhat, Paul Johnston, Muhammad Khurshid, Charlotte Barclay, Deepti Kapur, Helen Jeffrey, Anna Hughes, Lauren Slack, Eleri Thomas, Anna Royon, Angela Hall, Jon King, Sindi Nyathi, Vanessa Morris, Madhura Castelino, Ellie Hawkins, Linda Tomson, Animesh Singh, Annalyn Nunag, Stella O’Connor, Nathan Rushby, Nicola Hewitson, Kenny O’Sunmboye, Adam Lewszuk, Louise Boyles, Martin Perry, Emma Williams, Christine Graver, Emmanuel Defever, Sanjeet Kamanth, Dominic Kay, Joe Ogor, Louise Winter, Sarah Horton, Gillian Welch, Kath Hollinshead, James Peters, Julius Labao, Andrea Dmello, Julie Dawson, Denise Graham, Denise De Lord, Jo Deery, Tracy Hazelton, Miguel Ángel González‐Gay, Javier Martín, Ana Márquez, Martin Kerick +296 morewiley +1 more sourceEfficacy, safety and cost‐effectiveness of CAR‐T therapy
British Journal of Clinical Pharmacology, EarlyView.CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL.
Innovations target solid tumours despite challenges such as antigen escape.
Combination therapies enhance the delivery and infiltration of CAR T cells.
Toxicity, cost and resistance remain major barriers to clinical use.Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic +7 morewiley +1 more sourceEffect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults
British Journal of Clinical Pharmacology, EarlyView.Aim
To evaluate the effects of carbamazepine, a strong cytochrome P450 (CYP)3A4 inducer, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader. Methods
This was a phase 1, open‐label, fixed‐sequence, two‐period study in healthy adult participants.Hechuan Wang, Jennifer A. Winton, Kyle T. Matschke, Alexandre Stouffs, Kimberly C. Lee, Yuanyuan Zhang, Wenlian Qiao, Weiwei Tan +7 morewiley +1 more sourceHLA class-I-transgenic mice as model system to study MHC-restricted antigen recognition in man [PDF]
, 1990 A. McMichael, C. Botteron, Chamberlain J-W, Dill O, E. H. Weiss, Engelhard V H, F. Kievits, G. Brem, G. Riethmüller, G. Schliesser, Kievits F, Kievits K, Krimpenfort P, Le A-T, P. Ivanyi, Pohla H, Taurog J D, Thurau S R, Weiss E H, Weiss E H +19 morecore +1 more sourceHLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)
British Journal of Clinical Pharmacology, EarlyView.Carbamazepine is licensed in the United Kingdom for the treatment of epilepsy, bipolar disorder and trigeminal neuralgia. The related compounds oxcarbazepine and eslicarbazepine are licensed for the treatment of epilepsy. These drugs can cause immune‐mediated hypersensitivity reactions, which typically affect the skin, and can be of variable severity ...Lucy Galloway, Cinzia Dello Russo, Nicholas Bass, Elvira Bramon, Helen Cross, Natalie Curley, Sarah Curran, Helen Davies, Jana De Villiers, William Evans, Bernhard Frank, Alice Groves, Judith Hayward, Jon Higham, Dyfrig A. Hughes, Shwe Sin Kyaw, Anthony G. Marson, Ailsa McLellan, Seth Mensah, Francis O'Neill, Jane Sargison, Sanjay M. Sisodiya, Jill Swan, Joanna M. Zakrewska, Munir Pirmohamed +24 morewiley +1 more sourceNanomaterial‐based immune therapeutic strategies in neurodegenerative diseases
BMEMat, EarlyView.This review highlights the immunomodulatory potential of nanomaterials (NMs) in treating neurodegenerative diseases (NDs). It focuses on their roles in regulating innate and adaptive immune responses to maintain immune homeostasis. By providing insights into these mechanisms, the review lays the groundwork for innovative NMs therapeutic strategies to ...Xinru Zhou, Jia Liu, Shulin Lai, Suhan Yin, Bingmin Luo, Longquan Shao, Yiyuan Kang +6 morewiley +1 more sourceMimic, target, and adapt: Cell membrane‐coated nanoplatforms for precision and immune‐guided cancer treatment
BMEMat, EarlyView.This Perspective explores the emerging landscape of cell membrane‐coated nanoparticles (CM‐NPs) as intelligent, immune‐compatible platforms for cancer therapy. Highlighting design strategies, translational challenges, and competitive positioning, it outlines how integrating biomimetic targeting with advanced analytical and manufacturing tools could ...A. K. M. M. Alam, Xiaojun Cai, Malik Ihsan Ullah Khan, Robert Musiol, Quazi T. H. Shubhra +4 morewiley +1 more source
